Lung Cancer Screening Adherence Rates Decline Annually After Baseline Screening

Follow Drugslib on

Medically reviewed by Carmen Pope, BPharm. Last updated on March 20, 2025.

By Elana Gotkine HealthDay Reporter

THURSDAY, March 20, 2025 -- Screening adherence is associated with increased overall and early-stage lung cancer detection rates among individuals undergoing lung cancer screening (LCS); however, adherence rates appear to decrease following baseline screening, according to a study published online March 18 in JAMA Network Open.

Roger Y. Kim, M.D., from the University of Pennsylvania in Philadelphia, and colleagues conducted a retrospective cohort study involving adults aged 55 to 75 years who formerly or currently smoked and underwent baseline LCS (T0) between Jan. 1, 2015, and Dec. 31, 2018, to examine annual LCS adherence rates across two subsequent LCS rounds (T1 and T2).

Overall, 10,170 individuals received baseline LCS. The researchers found that during rounds T1 and T2, 61.2 and 50.5 percent of eligible patients were adherent, respectively. There was a significant association for T1 adherence with T2 adherence. A total of 2.7 percent of participants were diagnosed with lung cancer across 36 months of follow-up. During rounds T0, T1, and T2, incident lung cancer diagnosis rates were 1.3, 0.7, and 0.8 percent, respectively. Higher lung cancer diagnosis rates were seen among those who were LCS-adherent during both rounds T1 (1.0 versus 0.2 percent) and T2 (1.3 versus 0.2 percent). The proportion of early-stage lung cancers was higher among individuals adherent to screening at T2 versus those not adherent (73.0 versus 25.0 percent).

"The finding that annual LCS adherence rates decreased across subsequent rounds of screening supports the use of annual adherence as a quality metric for LCS programs seeking to maximize the benefits of LCS for early lung cancer detection and, ultimately, reduced lung cancer-related deaths," the authors write.

Several authors disclosed ties to the biopharmaceutical industry.

Abstract/Full Text

Editorial

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2025-03-21 06:00

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords